GOMEKLI (mirdametinib)

Dosing designed to fit your needs

Actor portrayal.

GOMEKLI (mirdametinib) comes with a built-in treatment break

GOMEKLI is taken by mouth twice a day (about 12 hours apart).

Each GOMEKLI dosing cycle is 28 days (4 weeks).

GOMEKLI is taken for the first 21 days, followed by 7 days when GOMEKLI is not taken.

The next cycle then begins with 21 days of treatment.

Your healthcare provider will decide the right dose of GOMEKLI based on weight and height (body surface area). It’s important to take GOMEKLI as directed by your healthcare provider.

GOMEKLI comes in two forms

Grape-flavored tablets

for oral suspension
""
Capsules that come in

two sizes
""
""
""

Tic Tac® and its three-dimensional design are registered trademarks of Ferrero S.A.

""
Oral suspension means the tablets mix or disperse into water, so the medicine can be taken as a liquid. This may make taking GOMEKLI easier for people who have difficulty swallowing. Tablets can also be swallowed whole.

GOMEKLI can be taken with or without food. No fasting is required

Preparing GOMEKLI tablets for liquid dosing

""

OR

""
""

Getting started guide

A brochure that has what you need and want to know about taking GOMEKLI.

""

Personalized treatment journal

A tool that helps you keep track of your experience with GOMEKLI to share with your care team.

Before starting GOMEKLI treatment

Your healthcare provider may order some tests before and during GOMEKLI treatment, including:

""

Echocardiogram

to look at the heart

""

Blood tests

""

Eye exam

to check your vision and the health of your eyes

""

Pregnancy test

for people who are able to become pregnant

Before taking GOMEKLI, tell your healthcare provider about all of your medical conditions.

SpringWorks CareConnections™ logo

Savings and support

SpringWorks CareConnections offers support and resources for people taking GOMEKLI.

What is GOMEKLI?

GOMEKLI (mirdametinib) is a prescription medicine used to treat adults and children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cause symptoms and cannot be completely removed by surgery.

It is not known if GOMEKLI is safe and effective in children under 2 years of age.

Important Safety Information

Before taking GOMEKLI, tell your healthcare provider about all of your medical conditions, including if you:

  • Have eye problems
  • Have heart problems
  • Are pregnant or plan to become pregnant. GOMEKLI can harm your unborn baby

    Females who are able to become pregnant:

    • Your healthcare provider should check to see if you are pregnant before you begin treatment with GOMEKLI.
    • Use effective birth control (contraception) during treatment with GOMEKLI and for 6 weeks after your last dose.
    • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with GOMEKLI.

    Males with female partners who are able to become pregnant:

    • Use effective birth control (contraception) during treatment with GOMEKLI and for 3 months after your last dose.
    • Tell your healthcare provider right away if your female partner becomes pregnant or thinks she may be pregnant during treatment with GOMEKLI.
  • Are breastfeeding or plan to breastfeed. It is not known if GOMEKLI passes into your breast milk.
    • Do not breastfeed during treatment with GOMEKLI and for 1 week after your last dose.
    • Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I take GOMEKLI?

  • Take GOMEKLI exactly as your healthcare provider tells you to take it. Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with GOMEKLI if you develop certain side effects.
  • Take GOMEKLI twice a day, about 12 hours apart, for 21 days, followed by 7 days off treatment, to complete a 28-day treatment cycle. Your healthcare provider will decide how many treatment cycles are right for you.
  • Take GOMEKLI with or without food.
  • GOMEKLI comes in two different dosage forms, GOMEKLI capsules and GOMEKLI tablets for oral suspension. Your healthcare provider will decide the dosage form and dose of GOMEKLI that is right for you.
  • If you take GOMEKLI capsules: Swallow each capsule whole with drinking water. If more than 1 capsule is required, swallow 1 capsule at a time. Do not open, break or chew the capsules.
  • If you take GOMEKLI tablets for oral suspension, either:
    • Swallow each tablet for oral suspension whole with drinking water. If more than 1 tablet is required, swallow 1 tablet at a time.
    • OR

    • Disperse the tablets for oral suspension in drinking water to make a liquid (suspension) before you take or give GOMEKLI.

    See the “Instructions for Use” that come with your medicine for instructions on how to prepare and take GOMEKLI tablets for oral suspension.

  • If you miss a dose of GOMEKLI, skip the missed dose and take your next dose at your regularly scheduled time.
  • If you vomit at any time after taking GOMEKLI, do not take an additional dose. Take your next dose at your regularly scheduled time.

What are the possible side effects of GOMEKLI?

GOMEKLI may cause serious side effects, including:
  • Eye problems. GOMEKLI may cause eye problems that can lead to blindness. Your healthcare provider will check your vision before and during treatment with GOMEKLI. Tell your healthcare provider right away if you get any of the following signs or symptoms of eye problems:
    • Blurred vision
    • Loss of vision
    • Other changes to your vision
  • Heart problems. GOMEKLI may lower the amount of blood pumped by your heart, which is common in children during treatment with GOMEKLI and can also be severe. Your healthcare provider will do tests before you start GOMEKLI treatment, every 3 months during your first year of treatment, and then as needed to make sure your heart is working properly. Tell your healthcare provider right away if you get any of the following signs or symptoms of heart problems:
    • Coughing or wheezing
    • Shortness of breath
    • Swelling of your ankles and feet
    • Tiredness
    • Increased heart rate
  • Skin problems. Skin rashes are common with GOMEKLI in both adults and children and can also be severe. GOMEKLI can also cause hair loss (alopecia). Tell your healthcare provider if you develop any of the following signs or symptoms of skin problems:
    • Flat skin rash
    • Raised bumps on the skin
    • Skin bumps that look like acne
    • Skin redness
    • Itchy rash
    • Peeling skin

The most common side effects of GOMEKLI in adults include:

  • Diarrhea
  • Nausea
  • Muscle, joint, and bone pain
  • Vomiting
  • Tiredness
The most common severe abnormal blood tests in adults include an increased enzyme called creatine phosphokinase (CPK).

The most common side effects of GOMEKLI in children include:

  • Diarrhea
  • Muscle, joint, and bone pain
  • Stomach (abdominal) pain
  • Vomiting
  • Headache
  • Skin redness, swelling, or pain around the fingernails or toenails
  • Nausea
The most common severe abnormal blood tests in children include decreased white blood cell (neutrophil) counts and increased CPK.
GOMEKLI may cause fertility problems in females, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.
These are not all of the possible side effects of GOMEKLI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is GOMEKLI?

GOMEKLI (mirdametinib) is a prescription medicine used to treat adults and children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cause symptoms and cannot be completely removed by surgery.

It is not known if GOMEKLI is safe and effective in children under 2 years of age.

Please click here for full Prescribing Information, including Patient Information and Instructions for Use.
Please click here for full Prescribing Information, including Patient Information and Instructions for Use.